SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study
Ana Lleò(Humanitas University), Savino Bruno(Humanitas University), Vincenza Calvaruso(University of Palermo), Maria Rendina, Andrea Aglitti(University of Salerno), V. Boccaccio(Humanitas University), Marcello Persico(University of Salerno), V. Di Marco(University of Palermo), Marco Zuin(University of Padua), Alessio Aghemo, Fabio Conti, Erica Villa(University of Modena and Reggio Emilia), Alessia Ciancio(Department of Medical Sciences), Alessia Giorgini(Università Cattolica del Sacro Cuore), Pietro Andreoné, B. Coco(Azienda Ospedaliera Universitaria Pisana), Maurizia Rossana Brunetto(University of Pisa), Luca Marzi(Azienda Ospedaliero-Universitaria di Modena), Elisabetta Degasperi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), S. Bollani(Azienda Ospedaliera Fatebenefratelli e Oftalmico), Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alfredo Di Leo(University Gastroenterology), Giulia Troshina(University of Turin), Patrick Maisonneuve(European Institute of Oncology)
Cited by 2
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Hereditary Pancreatitis and the Risk of Pancreatic Cancer
|JNCI Journal of the National Cancer Institute|1997|986
Development and Validation of a Food Frequency Questionnaire in Spain
|International Journal of Epidemiology|1993|933
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664